NCT06757881View on ClinicalTrials.gov

IL1RAP-targeting Chimeric Antigen Receptor T Cells in the Treatment of Relapsed/Refractory Hepatocellular Carcinoma

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

April 1, 2025

Study Completion Date

December 1, 2027

Conditions
HCC
Interventions
BIOLOGICAL

Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :1.0×10^8(First dose group)

Different dose groups

BIOLOGICAL

Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :2.5×10^8(Second dose group)

Different dose groups

BIOLOGICAL

Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :5.0×10^8（Third dose group）

Different dose groups

Trial Locations (1)

200000

Zhongshan Hospital Affiliated to Fudan University, Shanghai

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER